Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 180, P. 117483 - 117483
Published: Sept. 30, 2024
Language: Английский
Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101232 - 101232
Published: Feb. 1, 2025
Language: Английский
Citations
1
Marine Drugs, Journal Year: 2024, Volume and Issue: 22(7), P. 295 - 295
Published: June 26, 2024
Recently, the need to develop a robust three-dimensional (3D) cell culture system that serves as valuable in vitro tumor model has been emphasized. This should closely mimic growth behaviors observed vivo and replicate key elements characteristics of human tumors for effective discovery development anti-tumor therapeutics. Therefore, this study, we developed an 3D prostate cancer (PC) using marine collagen-based biomimetic scaffold. The displayed distinctive molecular profiles cellular properties compared with those 2D PC culture. was evidenced by (1) increased proliferation, migration, invasion, colony formation, chemoresistance; (2) upregulated expression crucial multidrug-resistance- cancer-stemness-related genes; (3) heightened molecules associated malignant progressions, such epithelial-mesenchymal transition transcription factors, Notch, matrix metalloproteinases, pluripotency biomarkers; (4) enrichment stem cells (CSCs); (5) enhanced integrins. These results suggest our potential serve research platform studying CSC biology, well screening novel therapies targeting CSCs.
Language: Английский
Citations
4
Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2797 - 2797
Published: Aug. 8, 2024
This review delves into the intricate roles of interleukin-8 (IL-8) and its receptors, CXCR1 CXCR2, in prostate cancer (PCa), particularly castration-resistant (CRPC) metastatic CRPC (mCRPC). emphasizes crucial role tumour microenvironment (TME) inflammatory cytokines promoting progression response to cell targeting agents. IL-8, acting through C-X-C chemokine receptor type 1 (CXCR1) 2 (CXCR2), modulates multiple signalling pathways, enhancing angiogenesis, proliferation, migration cells. highlights shift PCa research focus from solely cells non-cancer-cell components, including vascular endothelial cells, extracellular matrix, immune dynamic interactions within TME. The immunosuppressive nature TME significantly influences resistance emerging therapies. Current treatment modalities, androgen deprivation therapy chemotherapeutics, encounter persistent are complicated by cancer’s notably “immune-cold” nature, which limits system tumour. These challenges underscore critical need for novel approaches that both overcome enhance engagement therapeutic potential inhibiting IL-8 is explored, with studies showing enhanced sensitivity treatments, radiation inhibitors. Clinical trials, such as ACE trial, demonstrate efficacy combining CXCR2 inhibitors existing offering significant benefits, especially patients resistant PCa. also addresses chemokines, noting complexity precision avoid side effects optimize outcomes.
Language: Английский
Citations
4
BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 24, 2025
Prostate cancer is one of the most prevalent malignancies in men. Once prostate advances to castration-resistant (CRPC), 5-year survival rate can decrease as low 14 months. However, current primary diagnostic method, PSA testing, associated with a lengthy detection cycle, limited accuracy, and delays identifying disease progression. Consequently, there an urgent need develop imaging technique that enables early accurate diagnosis CRPC. First, immunofluorescence was used verify expression NRP2 on endothelial cells neovasculature increased progression cancer. Next, NRP2-modified microbubbles (MBsNRP2) were prepared, their specific targeting ability validated through parallel plate flow experiments. Subsequently, co-culture systems established. Based this, proangiogenic effect systematically explored, differential analyzed. A combination localization, cytometry, western blotting, angiogenesis assays used. Finally, subcutaneous tumor-bearing mouse model, ultrasound molecular (USMI) implemented, contrast intensity attached MBsNRP2 monitored quantitatively This study confirmed clear colocalization CD31 tissues. Secondly, exhibited binding under dynamic conditions microvascular (HMEC-1). CRPC, HMEC-1 gradually increased, accompanied by significant enhancement angiogenic capacity. Lastly, compared control mice, USMI signals mice from hormone-sensitive (HSPC), non metastatic, (nmCRPC), (mCRPC) groups significantly increased. finding provides potential new pathway for clinical development Regarding cancer, neovascular increases, potentially serving target The has differences models at different stages. These findings suggest based could be novel strategy
Language: Английский
Citations
0
Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)
Published: Oct. 23, 2024
Currently, despite the vast amounts of time and money invested in cancer treatment, remains one primary threats to human life. The factor contributing low treatment efficacy is heterogeneity. unclear molecular mechanisms underlying tumorigenesis, coupled with complexity physiology, inability animal models accurately replicate tumor microenvironment, pose significant hurdles development novel therapies. Tumor-microenvironment-on-chip (TMOC) represents a research platform that integrates three-dimensional cell culture microfluidic systems, simulating essential components physiological traits vivo microenvironment. It offers dynamic setting within chip system study progression, potentially heralding breakthrough research. In this review, we will summarize current advancements platform, encompassing various types TMOCs their applications different cancer. From our perspective, TMOC necessitates enhanced integration tissue engineering techniques microphysiological environments before it can evolve into more refined preclinical model for
Language: Английский
Citations
3
Genes, Journal Year: 2025, Volume and Issue: 16(2), P. 180 - 180
Published: Feb. 1, 2025
Prostate cancer (PCa) patients who do not respond to androgen deprivation therapy (ADT), referred as castration-resistant prostate (CRPC), remain a clinical challenge due confirm the aggressive nature of CRPC and its resistance conventional therapies. This study aims investigate potential microRNAs (miRNAs) biomarkers for predicting therapeutic response in patients. We performed miRNA mRNA expression analyses using publicly available datasets applied 3D cell culture models replicate more physiologically relevant tumor conditions. Genetic analysis techniques were employed on data, profiles from examined. Eighteen miRNAs with differential identified between responded favorably abiraterone (responders) those advanced (non-responders). Specifically, such hsa-miR-152-3p hsa-miR-34a-3p found be associated critical pathways, including TGF-β signaling P53, which are linked resistance. Several predictors treatment efficacy, therapies like abiraterone. These results indicate that could serve non-invasive outcomes, facilitating personalized approach treatment. provides novel perspective strategies CRPC, emphasizing role improving precision efficacy this complex disease.
Language: Английский
Citations
0
Annals of Medicine, Journal Year: 2024, Volume and Issue: 57(1)
Published: Dec. 23, 2024
Background Increasing evidence indicates that cancer stem cells (CSCs) and stem-like form a special subpopulation of are ubiquitous in tumors. These exhibit similar characteristics to those normal tissues; moreover, they capable self-renewal differentiation, as well high tumorigenicity drug resistance. In prostate (PCa), it is difficult kill these using androgen signaling inhibitors chemotherapy drugs. Consequently, the residual (PCSCs) mediate tumor recurrence progression.
Language: Английский
Citations
1
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 180, P. 117483 - 117483
Published: Sept. 30, 2024
Language: Английский
Citations
0